ARQT实时信号 | 通过Getagraph.com最大化利润

购买 31874 min ago

@ $12.30

发出时间: 12 Apr 2024 @ 00:30

回报率: -34.63%

上一信号: Apr 11 - 22:25

上一信号: 出售

回报率: -0.89 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:44):

Stats
今日成交量	1.77M
平均成交量	3.87M
市值	924.37M
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $-0.600 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.13
ATR14	$0.0110 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Topper David Joseph	Buy	310 000	Stock Option (right to buy)
2024-04-10	Topper David Joseph	Buy	110 000	Common Stock
2024-04-10	Topper David Joseph	Sell	7 500	Stock Option (right to buy)
2024-03-04	Matsuda Masaru	Sell	3 760	Common Stock
2024-03-04	Burnett Patrick	Sell	4 782	Common Stock

INSIDER POWER
30.74
Last 98 transactions
Buy: 3 267 821 \| Sell: 1 662 580

音量相关性

長: -0.28 (neutral)

短: -0.14 (neutral)

Signal:(38.468) Neutral

Arcutis Biotherapeutics 相关性

10 最正相关
UCTT	0.963
MRUS	0.96
LRCX	0.958
DEMZ	0.954
SAIA	0.954
LCUT	0.953
LRGE	0.952
KRTX	0.952
META	0.951
FTC	0.95

10 最负相关
BIOL	-0.959
WISA	-0.948
RMRM	-0.948
DSWL	-0.947
CYXT	-0.946
SGLB	-0.945
KRKR	-0.942
LSAQ	-0.937
CRCT	-0.935
SRNGW	-0.931

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Arcutis Biotherapeutics 相关性 - 货币/商品

0.22
( neutral )

0.31
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.45
( neutral )

0.43
( neutral )

Arcutis Biotherapeutics 财务报表

Annual	2023
营收:	$59.61M
毛利润:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2023
营收:	$59.61M
毛利润:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2022
营收:	$3.69M
毛利润:	$2.93M (79.54 %)
EPS:	$-5.84

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.79

Financial Reports:

No articles found.

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.